ConductScience.org, home

Paper33832018

[Multi-disciplinary expert consensus on the optimal clinical use of the polymyxins in China].

Infectious Diseases Society of China and 6 others. Zhonghua Jie He He Hu Xi Za Zhi, 2021. Cited by 38 papers, by iCite.

Cite this record

ConductScience Library. [Multi-disciplinary expert consensus on the optimal clinical use of the polymyxins in China]. Papers, record 33832018. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33832018

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
[Multi-disciplinary expert consensus on the optimal clinical use of the polymyxins in China].
PubMed
Journal
Zhonghua Jie He He Hu Xi Za Zhi
PubMed
Year
2021
PubMed
Publication types
Journal Article, Consensus Statement
PubMed
Citations, by iCite
38
iCite
Relative citation ratio, by iCite
3.38
iCite
Revised in PubMed
2026-03-04
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Infectious Diseases Society of ChinaGroup
2Chinese Thoracic SocietyGroup
3Chinese Society of Critical Care MedicineGroup
4Chinese Society of HematologyGroup
5Chinese Society of Bacterial Infection and ResistanceGroup
6Committee of Drug Clinical Evaluate Research of Chinese Pharmaceutical AssociationGroup
7Global Chinese Association of Clinical Microbiology and Infectious DiseasesGroup

Source PubMed

Download CSV of authors

Topics2

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
PolymyxinsMajor topic
China

Cited by23

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 38 citations.

PMIDTitleJournalYearIn PapersSource
42244289Clinical efficacy and risk factors of colistin sulfate in the treatment of carbapenem-resistant Gram-negative bacilli infections: A retrospective study.Zhong Nan Da Xue Xue Bao Yi Xue Ban2026https://conductscience.org/library/papers/42244289PubMed
42215914A successful individualized comprehensive therapy for carbapenem-resistant Klebsiella pneumoniae induced multifocal brain abscesses: a case report and literature review.BMC Infect Dis2026https://conductscience.org/library/papers/42215914PubMed
42180693Polymyxin B-induced acute kidney injury in a burn patient: a case report and pharmaceutical care.Front Med (Lausanne)2026https://conductscience.org/library/papers/42180693PubMed
41958927Commentary: Efficacy, safety, and therapeutic drug monitoring of polymyxin B sulfate and colistin sulfate in critically ill patients: a real-world retrospective study.Front Pharmacol2026https://conductscience.org/library/papers/41958927PubMed
41899205Sulbactam-Durlobactam in the Treatment of Bloodstream Infection Due to Carbapenem-Resistant Acinetobacter baumannii: A Case Series and Literature Review.J Clin Med2026https://conductscience.org/library/papers/41899205PubMed
41201487Nephrotoxicity of polymyxin B and colistin sulfate in patients with multidrug-resistant gram-negative bacteria infections: a parametric time-to-event analysis.Int J Clin Pharm2026https://conductscience.org/library/papers/41201487PubMed
41013329
The relationship between the alveolar epithelial lining fluid concentration of intravenous plus inhaled polymyxin B and clinical efficacy in patients with pneumonia caused by carbapenem-resistant gram-negative bacilli: a prospective cohort study.
BMC Infect Dis2025https://conductscience.org/library/papers/41013329PubMed
40980916Comparison of different colistin sulfate regimens for carbapenem-resistant gram-negative bacteria pneumonia in neurocritical care patients: a retrospective cohort study.Antimicrob Agents Chemother2025https://conductscience.org/library/papers/40980916PubMed
40974395Optimizing Polymyxin B Therapy in Critical Care: Pharmacokinetic Insights and Clinical Outcomes in a Retrospective Cohort Study.Infect Dis Ther2025https://conductscience.org/library/papers/40974395PubMed
40895544Case Report: Polymyxin E-associated reversible leukopenia.Front Immunol2025https://conductscience.org/library/papers/40895544PubMed
40419663Population pharmacokinetics of colistin sulfate in critically ill patients based on NONMEM.Sci Rep2025https://conductscience.org/library/papers/40419663PubMed
40170884Aerosolized delivery resulting in high polymyxin B concentration levels in epithelial lining fluid ensures efficacy in ventilator-associated pneumonia.JAC Antimicrob Resist2025https://conductscience.org/library/papers/40170884PubMed
40092845Temporal Shifts in Etiological Agents and Trends in Antimicrobial Resistance of Bloodstream Infection in Southwest China from 2016 to 2023.Infect Drug Resist2025https://conductscience.org/library/papers/40092845PubMed
39830357Efficacy, safety, and therapeutic drug monitoring of polymyxin B sulfate and colistin sulfate in critically ill patients: a real-world retrospective study.Front Pharmacol2024https://conductscience.org/library/papers/39830357PubMed
39174888Antibiotic resistance and epidemiological characteristics of polymyxin-resistant Klebsiella pneumoniae.Zhong Nan Da Xue Xue Bao Yi Xue Ban2024https://conductscience.org/library/papers/39174888PubMed
38974043Polymyxins: recent advances and challenges.Front Pharmacol2024https://conductscience.org/library/papers/38974043PubMed
38212555Clinical Efficacy and Safety of Colistin Sulfate in the Treatment of Carbapenem-Resistant Organism Infections in Patients with Hematological Diseases.Infect Dis Ther2024https://conductscience.org/library/papers/38212555PubMed
37878197Ceftazidime-avibactam versus polymyxins in treating patients with carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis.Infection2024https://conductscience.org/library/papers/37878197PubMed
36643845Efficacy and safety of polymyxin E sulfate in the treatment of critically ill patients with carbapenem-resistant organism infections.Front Med (Lausanne)2022https://conductscience.org/library/papers/36643845PubMed
36176436Commentary: Population pharmacokinetics of colistin sulfate in critically ill patients: Exposure and clinical efficacy.Front Pharmacol2022https://conductscience.org/library/papers/36176436PubMed

See all 23 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33832018

GET https://conductscience.org/api/papers/v1/33832018/cited_by?page=2